Susanna Naggie, MD

Associate Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail Dcri-2400 Pratt Street, Room 0311-BOX 3850, Durham, NC 27710
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Naggie, S, Marks, KM, Hughes, M, Fierer, DS, Macbrayne, C, Kim, A, Hollabaugh, K, Roa, J, Symonds, B, Brainard, DM, McHutchison, JG, Peters, MG, Kiser, JJ, Chung, R, and AIDS Clinical Trials Group (ACTG) A5327 Study Team, . "Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C." April 2017.

PMID
28329053
Full Text

Chan, A, Patel, K, and Naggie, S. "Genotype 3 Infection: The Last Stand of Hepatitis C Virus." Drugs 77, no. 2 (February 2017): 131-144. (Review)

PMID
28074358
Full Text

Ho, SB, Monto, A, Peyton, A, Kaplan, DE, Byrne, S, Moon, S, Copans, A, Rossaro, L, Roy, A, Le, H, Dvory-Sobol, H, Zhu, Y, Brainard, DM, Guyer, W, Shaikh, O, Fuchs, M, Morgan, TR, and VALOR study team, . "Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities." Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association 15, no. 2 (February 2017): 282-288.

PMID
27237429
Full Text

Naggie, S. "Hepatitis C Virus, Inflammation, and Cellular Aging: Turning Back Time." Topics in Antiviral Medicine 25, no. 1 (February 2017): 3-6. (Review)

PMID
28402927
Scholars@Duke

Naggie, S, and Muir, AJ. "Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs." Annual Review of Medicine 68 (January 2017): 345-358. (Review)

PMID
27686017
Full Text

Naggie, S, Holland, DP, Sulkowski, MS, and Thomas, DL. "Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 64, no. 1 (January 2017): 92-99. (Review)

PMID
27682067
Full Text

Alam, I, Brown, K, Donovan, C, Forlenza, J, Lauwers, K, Mah'moud, MA, Manch, R, Mohanty, SR, Prabhakar, A, Reindollar, R, DeMasi, R, Slim, J, Tandon, N, Villadiego, S, and Naggie, S. "Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study." Open Forum Infectious Diseases 4, no. 1 (January 2017): ofw258-null.

PMID
28480251
Full Text

Younossi, ZM, Stepanova, M, Sulkowski, M, Naggie, S, Henry, L, and Hunt, S. "Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus." November 2016.

PMID
27291391
Full Text

Younossi, ZM, Stepanova, M, Sulkowski, M, Naggie, S, Henry, L, and Hunt, S. "Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus." JOURNAL OF VIRAL HEPATITIS 23, no. 11 (November 2016): 857-865.

Full Text

Sulkowski, MS, Cooper, C, Molina, J-M, Naggie, S, Huang, KC, Osinusi, AO, Stamm, LM, Massetto, B, McNally, J, Brainard, DM, McHutchison, JG, Wyles, DL, Rockstroh, JK, and Dieterich, DT. "High Rates of Medical and Psychiatric Comorbidities in HIV/HCV Coinfected Patients Treated With Sofosbuvir-Containing Regimens in Registrational Clinical Trials." October 2016.

Scholars@Duke

Pages